TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years of age or greater.~* Histologically or cytologically proven non-small cell lung cancer that is either metastatic or recurrent and failed at least one prior platinum-based chemotherapeutic regimen.~* Patients who have recurred after previous surgery and/or radiation may participate in this trial.~* Patients may have had prior neoadjuvant or adjuvant therapy.~* Patients with known brain metastases are eligible for this clinical trial if their disease has been treated and they are clinically stable and documented by a stable or improved pretreatment CT or MRI scan of the brain to evaluate for CNS disease within 28 days prior to registration.~* Measurable OR non-measurable disease documented by CT, MRI, X-ray or nuclear exam (FDG-PET). Measurable or non-measurable disease must be present outside the area of surgical resection. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease.~* Progression after at least one prior platinum-based chemotherapy.~* Greater than 3 weeks since surgery and must have recovered from all associated toxicities at time of registration.~* ANC ≥ 1,500/µl and platelet count ≥ 100,000/µl obtained within 28 days prior to registration.~* Adequate hepatic function documented by a serum bilirubin ≤ 1.5 times institutional upper limit of normal and liver enzymes (SGOT or SGPT) ≤ 2.5 x the institutional upper limit of normal obtained within 28 days prior to registration.~* Patients requiring lung radiation must have an FEV1 of \> 1000 liters obtained within 28 days prior to registration and must have pulmonary function tests with DLCO.~* Zubrod Performance Status of 0,1 or 2.~Exclusion Criteria:~* No prior single-agent, weekly Docetaxel chemotherapy.~* Peripheral neuropathy ≥ Grade 1.~* Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission or other cancer from which the patient has been disease-free for 5 years.~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed locally advanced (stage III or IV) squamous cell carcinoma of the mouth, oropharynx, hypopharynx, or larynx scheduled to be treated with concomitant chemoradiation including Cisplatin100 mg/m2 3 times~* Normal otoscopic findings and symmetrical hearing~Exclusion Criteria:~* Karnofsky below 70

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated ear (Type: EXPERIMENTAL): Trans-tympanic injection of a sodium thiosulfate gel
- Control ear (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient falling within age group with granulation tissue around G tube site~Exclusion Criteria:~* Patients falling outside of age group range

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Silver Nitrate (Type: ACTIVE_COMPARATOR): Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
- Kenalog (Triamcinolone) (Type: ACTIVE_COMPARATOR): Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
- Washcloth Abrasion (Type: ACTIVE_COMPARATOR): Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton Pregnancy~* 37.0 and 41.0 gestational age~* Confirmed Rupture of Membranes~* Group B Streptococcus Negative~* Cephalic Presentation~* Absence of contractions for at least 60 minutes following rupture~* Absence of contractions at time of enrolment~Exclusion Criteria:~* Contraindication to Vaginal Delivery~* Previous Uterine Surgery, including Caesarean Section~* Previous Cerclage, Cone Biopsy, LEEP, or Cervical Surgery~* Documented history of cervical incompetence~* High Grade intraepithelial lesion, adenocarcinoma in situ, or invasive cervical cancer.~* Immunosuppressed State~* Active Vaginal Infection

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxytocin (Type: ACTIVE_COMPARATOR): Induction of Labour with Oxytocin Alone
- Intracervical Catheter (Type: EXPERIMENTAL): Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Follicular Flushing in Patients With Suboptimal Responses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of women \<43 years~2. Normal uterine cavity on saline sonogram~3. Endometrial thickness \>=8mm on the day of hCG~Exclusion Criteria:~1. Planned not to have fresh embryo transfer~2. Cycle cancelled prior to hCG administration~3. Natural cycle IVF~4. Presence of hydrosalpinges on scanning which are not surgically treated~5. Presence of endometrial polyps on scanning~6. Undergoing preimplantation genetic diagnosis

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Non-flushing group (Type: PLACEBO_COMPARATOR): Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
- Flushing group (Type: ACTIVE_COMPARATOR): aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically confirmed and recurrent epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma requiring secondary debulking. Last chemotherapy of primary treatment was finished at least 6 months before.~* Patient must give written informed consent before registration~* WHO/ECOG performance status 0 - 1~* Age ≥18 years, ≤70 years~* Adequate hematological values: leukocytes ≥3x10\^9/l, thrombocytes ≥100x10\^9/l~* Adequate renal function. Obstructive hydronephrosis as a cause of borderline (30 - 45 ml/min) renal function should be investigated and treated prior to study entry.~* Patient compliance and geographic proximity allow proper staging and follow-up.~* FIGO III and IV~Exclusion Criteria:~* Primary diagnosis of epithelial ovarian cancer, or primary treatment completed less than 6 months ago.~* FIGO stage I + II~* Distant and current metastases~* WHO/ECOG performance status ≥2~* Inadequate hepatic function: bilirubin \>1.5x ULN (upper limit normal range) or ASAT/ALAT \>2.5x ULN or AP \>5x ULN~* Psychiatric disorder precluding understanding of information of trial related topics or giving informed consent~* Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry~* Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes)~* Known hypersensitivity to cisplatin~* Any concomitant drugs contraindicated for use with the trial drugs according to the Swissmedic-approved product information~* Dehydration~* Impaired hearing or symptomatic peripheral neuropathy: ≥grade II NCI-CTCAEv3~* Regular use of anti-epileptics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HIPEC treatment (Type: EXPERIMENTAL): Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Depression Medication Choice Decision Aid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Already have or receive a depression diagnosis (according to the treating clinician)~* Speak English of French~* Have no major obstacles providing clear written consent~* Discuss the possibility of taking antidepressants during the clinical encounter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Participants in this arm will receive care as usual.
- Depression Medication Choice (Type: EXPERIMENTAL): Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known DM2 (receiving lifestyle management and/or metformin and/or sulfonylurea~* Stable therapy for DM2 for the past 3 months~* All other medications and doses stable for past 3 months~* HbA1c 8.9% or lower (can be done in past 30 days)~* Known NASH based on the accepted American Gastroenterological Association Criteria:~  1. Alcohol consumption (\< 10g/day in women and \<20g/day in men)~ 2. Cause of liver disease other than NAFLD (negative investigations for: viral hepatitis, iron overload, a-1 antitrypsin, ceruloplasmin, autoimmune disease)~ 3. Liver histology demonstrating macrovesicular fatty change of hepatocytes, with evidence of steatohepatitis, manifested by the presence of Mallory Bodies, ballooning degeneration, lobular neutrophilic inflammation and perisinusoidal fibrosis. (If liver biopsy done within 2 years prior to screening for this trial, that biopsy will be reviewed to ensure it meets criteria for diagnosis).~Exclusion Criteria:~* Any contraindication for undergoing MRI~* Child class B or C cirrhosis~* Participation in another clinical trial~* Use of thiazoledinedione (rosiglitazone or pioglitazone) in past 6 months~* Current use of plavix~* Previous exposure to sitagliptin~* Prior history of pancreatitis~* History of anaphylaxis to another Canadian-marketed DPP-IV inhibitor (saxagliptin)~* Creatine clearance \<30 ml/min~* Anaemia (haemoglobin \< 110 mg/dL)~* Platelet count \< 50 000 cells/mm3~* Known heart or kidney failure~* Comorbid condition that decreases natural life span (e.g. known cancer)~* Pregnant or breastfeeding or wishing to become pregnant in the next 6 months~* Current or past treatment with medications that can induce steatohepatitis (e.g. glucocorticoids, methotrexate, amiodarone etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin (Type: EXPERIMENTAL): sitagliptin 100mg/daily for 6 months
- placebo (Type: PLACEBO_COMPARATOR): placebo match for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric REPlAcement of the PulmonaRy ValvE in Tetralogy of Fallot -

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females with repaired Tetralogy of Fallot (TOF), currently between 13 and 21 years of age.~2. On clinical Cardiac Magnetic Resonance (CMR) : Right Ventricular End-Diastolic Volume Index (RVEDVi) between 140 and 180 cc/m2 inclusive with Right Ventricular End-Diastolic Function (RVEF) \> 40% and Left Right Ventricular End-Diastolic (LVEF ) \> 50%, RV outflow tract peak velocity \< 3 meters/second (if not available this will be skipped); there will be no indexed Right Ventricular end-systolic volume (RVESVi) criteria; by defining RVEDVi and RVEF, Investigators will be inherently defining RVESVi~3. On clinical echocardiogram: RV outflow tract peak velocity \< 3 meters/second (if not available this will be skipped), at least mild pulmonary insufficiency and tricuspid regurgitation with an RV pressure estimate \< 1/2 systemic pressure.~4. On Exercise Stress Test (EST), aerobic capacity \> 60% of predicted.~5. No Q-wave, R-wave, S-wave (QRS) duration criteria on ECG.~Exclusion Criteria:~1. Any condition judged by the patient's physician that would cause this trial to be detrimental to the patient.~2. Specific forms of TOF excluded are those with endocardial cushion defects, TOF with absent pulmonary valve and TOF with multiple aorto-pulmonary collaterals requiring unifocalization.~3. Unilateral branch pulmonary artery stenosis (one lung receives \< 25% of total flow)~4. Contraindication to non-sedated exercise CMR (e.g. pacemaker/implanted cardioverter defibrillator); need for sedation~5. If data available, moderate or greater tricuspid regurgitation on echocardiogram or CMR or Qp/Qs \> 1.5~6. Significant strokes/hemiplegia or inability to exercise~7. Genetic syndrome/developmental delay which would make QOL and EST date uninterpretable~8. Pregnancy~9. Previous pulmonary valve replacement (PVR)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- PVR Arm (Type: OTHER): PVR arm will undergo PVR via catheter or surgery
- No PVR (Type: NO_INTERVENTION): No PVR group will continue with medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Respiratory Training Protocols on GH Secretion in Obesity (ALRESPGHOB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI standard deviation score (SDS) \> 2 for subjects aged \< 18 years and BMI \> 35 for patients aged \>18 years;~* absence of structured physical activity programs (regular activity for more than 120 minutes/week) during the 6 months preceding the study;~* absence of signs/symptoms referable to cardiovascular, respiratory, gastrointestinal, or musculoskeletal pathologies contraindicated for carrying out the tests.~Exclusion Criteria:~* age \< 14 years and \> 30 years;~* presence of structured physical activity programs (regular activity for more than 120 minutes/week) during the 6 months preceding the study;~* presence of signs/symptoms referable to cardiovascular, respiratory, gastrointestinal, or musculoskeletal pathologies contraindicated for carrying out the tests.

- Gender: MALE
- Minimum Age: 14 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Control group (CTRL) (Type: OTHER): None
- Experimental group (RMT) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Psilocybin in Concussion Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of post-traumatic headache~* Typical pattern of headache attacks with approximately two attacks or more weekly~* Attacks are managed by means involving no more than twice weekly triptan use~Exclusion Criteria:~* Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)~* Axis I psychotic disorder in first degree relative~* Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology~* Pregnant, breastfeeding, lack of adequate birth control~* History of intolerance to psilocybin, LSD, or related compounds~* Drug or alcohol abuse within the past 3 months (excluding tobacco)~* Urine toxicology positive to drugs of abuse~* Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days~* Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks~* Use of antidepressant medication (i.e. TCA, MAOI, SSRI) in the past 6 weeks~* Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Low Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
- Placebo/High Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
- Low Dose Psilocybin/Placebo (Type: EXPERIMENTAL): Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
- High Dose Psilocybin/Placebo (Type: EXPERIMENTAL): Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
- High Dose Psilocybin/Low Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
- Low Dose Psilocybin/High Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed AJCC Stage IIIB, IIIC or IV melanoma with injectable metastases (in transit, intradermal, or subcutaneous nodules)~* Tumor accessible to intra-tumoral injections~* Cumulative tumor volume great enough to accept MORAb-028 injections for a given dose level, based on intent to inject at a concentration of 1 mg/cm3~Exclusion Criteria:~* Are candidates for curative surgical excision or lymphadenectomy~* Prior non-surgical treatment within 4 weeks~* Known central nervous system (CNS) tumor involvement or metastases~* Hypersensitivity to MORAb-028

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MORAb 028 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy